{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Primary+Malignant+Central+Nervous+System+Neoplasm&page=2", "query": { "condition": "Advanced Primary Malignant Central Nervous System Neoplasm", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Primary+Malignant+Central+Nervous+System+Neoplasm&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T20:34:48.130Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03220035", "title": "Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma", "Ependymoma", "Ewing Sarcoma", "Hepatoblastoma", "Langerhans Cell Histiocytosis", "Malignant Germ Cell Tumor", "Malignant Glioma", "Osteosarcoma", "Peripheral Primitive Neuroectodermal Tumor", "Recurrent Childhood Central Nervous System Neoplasm", "Recurrent Childhood Non-Hodgkin Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Neuroblastoma", "Refractory Malignant Solid Neoplasm", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Primary Central Nervous System Neoplasm", "Rhabdoid Tumor", "Rhabdomyosarcoma", "Soft Tissue Sarcoma", "Wilms Tumor" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 4, "start_date": "2017-11-08", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2025-01-27", "last_synced_at": "2026-06-25T20:34:48.130Z", "location_count": 114, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03220035" }, { "nct_id": "NCT03155620", "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Histiocytic Sarcoma", "Juvenile Xanthogranuloma", "Langerhans Cell Histiocytosis", "Malignant Glioma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Glioma", "Recurrent Hepatoblastoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Primary Central Nervous System Neoplasm", "Recurrent Rhabdoid Tumor", "Recurrent Soft Tissue Sarcoma", "Refractory Ewing Sarcoma", "Refractory Glioma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Primary Central Nervous System Neoplasm", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Rhabdoid Tumor", "Stage III Osteosarcoma AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Osteosarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Stage IVA Osteosarcoma AJCC v7", "Stage IVB Osteosarcoma AJCC v7", "Wilms Tumor" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ensartinib", "type": "DRUG" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Ivosidenib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Larotrectinib Sulfate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mutation Carrier Screening", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Samotolisib", "type": "DRUG" }, { "name": "Selpercatinib", "type": "DRUG" }, { "name": "Selumetinib Sulfate", "type": "DRUG" }, { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Tipifarnib", "type": "DRUG" }, { "name": "Ulixertinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 1377, "start_date": "2017-07-31", "completion_date": "2027-01-06", "has_results": true, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-25T20:34:48.130Z", "location_count": 168, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03155620" }, { "nct_id": "NCT04171895", "title": "Communication Training for Caregivers In Advanced Care Planning", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Primary Malignant Brain Tumors", "Advanced Care Planning" ], "interventions": [ { "name": "Questionnaires", "type": "OTHER" }, { "name": "Communication training Part 1 (no longer recruiting)", "type": "OTHER" }, { "name": "Enhanced usual care", "type": "OTHER" }, { "name": "Communication training Part II", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2019-11-19", "completion_date": "2024-08-22", "has_results": false, "last_update_posted_date": "2024-08-26", "last_synced_at": "2026-06-25T20:34:48.130Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04171895" }, { "nct_id": "NCT04771520", "title": "Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Melanoma", "Locally Advanced Primary Malignant Central Nervous System Neoplasm", "Locally Advanced Sarcoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Primary Malignant Central Nervous System Neoplasm", "Metastatic Sarcoma", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Avapritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-01-20", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-06-25T20:34:48.130Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04771520" }, { "nct_id": "NCT00003067", "title": "Biological Therapy in Treating Patients With Primary or Advanced Glioma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "lymphokine-activated killer cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1997-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-02-09", "last_synced_at": "2026-06-25T20:34:48.130Z", "location_count": 1, "location_summary": "Staten Island, New York", "locations": [ { "city": "Staten Island", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003067" }, { "nct_id": "NCT01976910", "title": "Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer\"", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "DM-CHOC-PEN", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DEKK-TEC, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2010-09", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2020-08-04", "last_synced_at": "2026-06-25T20:34:48.130Z", "location_count": 1, "location_summary": "New Orleans, Louisiana", "locations": [ { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01976910" }, { "nct_id": "NCT03899792", "title": "A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Medullary Thyroid Cancer", "Infantile Myofibromatosis", "Infantile Fibrosarcoma", "Papillary Thyroid Cancer", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "Selpercatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Months to 21 Years" }, "enrollment_count": 36, "start_date": "2019-06-13", "completion_date": "2029-05", "has_results": true, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-06-25T20:34:48.130Z", "location_count": 12, "location_summary": "Los Angeles, California • Aurora, Colorado • Orlando, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03899792" }, { "nct_id": "NCT05969860", "title": "At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Anal Carcinoma", "Advanced Biliary Tract Carcinoma", "Advanced Bladder Carcinoma", "Advanced Breast Carcinoma", "Advanced Carcinoid Tumor", "Advanced Cervical Carcinoma", "Advanced Colorectal Carcinoma", "Advanced Gastric Carcinoma", "Advanced Glioblastoma", "Advanced Head and Neck Carcinoma", "Advanced HER2 Positive Breast Carcinoma", "Advanced Lung Carcinoma", "Advanced Lung Small Cell Carcinoma", "Advanced Malignant Germ Cell Tumor", "Advanced Malignant Solid Neoplasm", "Advanced Neuroendocrine Carcinoma", "Advanced Ovarian Carcinoma", "Advanced Pancreatic Carcinoma", "Advanced Prostate Small Cell Neuroendocrine Carcinoma", "Advanced Prostate Carcinoma", "Hematopoietic and Lymphoid System Neoplasm", "Multiple Myeloma", "Myelodysplastic Syndrome", "Advanced Basal Cell Carcinoma", "Advanced Cholangiocarcinoma", "Advanced Endometrial Carcinoma", "Advanced Esophageal Carcinoma", "Advanced Fallopian Tube Carcinoma", "Advanced Hepatocellular Carcinoma", "Advanced Liver Carcinoma", "Advanced Lymphoma", "Advanced Malignant Testicular Neoplasm", "Advanced Melanoma", "Advanced Merkel Cell Carcinoma", "Advanced Penile Carcinoma", "Advanced Primary Malignant Central Nervous System Neoplasm", "Advanced Renal Cell Carcinoma", "Advanced Sarcoma", "Advanced Skin Squamous Cell Carcinoma", "Advanced Urethral Carcinoma", "Advanced Vaginal Carcinoma", "Advanced Vulvar Carcinoma", "Advanced Appendix Carcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Clinical Encounter", "type": "PROCEDURE" }, { "name": "Home Health Encounter", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2023-08-23", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-06-25T20:34:48.130Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Grand Forks, North Dakota", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Grand Forks", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05969860" }, { "nct_id": "NCT01048008", "title": "Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Brain Involvement" ], "interventions": [ { "name": "DM-CHOC-PEN", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DEKK-TEC, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2010-09", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2020-08-04", "last_synced_at": "2026-06-25T20:34:48.130Z", "location_count": 1, "location_summary": "New Orleans, Louisiana", "locations": [ { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01048008" }, { "nct_id": "NCT04521686", "title": "Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cholangiocarcinoma", "Chondrosarcoma", "Glioma", "Any Solid Tumor" ], "interventions": [ { "name": "LY3410738", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2020-10-01", "completion_date": "2026-05", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-06-25T20:34:48.130Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04521686" } ] }